Q3 2025 Earnings Presentation

November 6, 2025

Disclaimer

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Forward-looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", approximate", expect", "may", "will", "project", "predict", "potential", "targeting", "intend", "could", "might", "should", "believe", "would" and similar expressions. Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of the management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the risks associated with: primary healthcare sector in general; competition; that future results may vary from historical results; the availability and effective integration and operation of management information systems and other technologies; ability to mitigate against cyber security risks; ability to access sufficient capital from internal and external sources; changes in legislation, including but not limited to tax laws; and government regulations. Accordingly, readers should not place undue reliance on the forward- looking statements, timelines and information contained in this presentation. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward-looking statements and information contained in this presentation are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events, or otherwise, unless so required by applicable securities laws or the TSX Exchange. The forward-looking statements or information contained in this presentation are expressly qualified by this cautionary statement. The TSX Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved of the contents of this presentation.

WELL Q3 2025 Key Financial Highlights

Q3 Revenue	Q3 Adj. EBITDA	Q3 Adj. Gross Margin
$364.6M	$59.9M	45.5%
+56% Y/Y	+296% Y/Y	+500 bps Y/Y

Q3 Revenue exc. CM Impact[1]	Q3 Adj. EBITDA exc. CM Impact[2]	Q3 FCFA2S
$347.0M	$42.3M	$15.1M
+48% Y/Y	+180% Y/Y	Inc. CRH Divestiture $30.2M

1) *The impact from Circle Medical revenue deferrals is removed in Q3-25*
2) *The impact from Circle Medical revenue deferrals is removed from both Q3-25 and Q3-24 comparative period*

WELL Q3 2025 Operational Highlights[1]

4,500+
Providers in WELL's Clinic Network[2]
(1,300+ physicians in CA)

43,000+
Unique Providers supported by WELL's Technology

2.7M+
Total Care Interactions
+29% YoY
(+19% organic)

1.7M+
Patient visits (CAN + US)
+19% YoY
(+3% organic)

1.08M
CAN patient visits
in Q3-25

+38%
YoY CAN patient visit growth
(+9% organic)

1) *All figures exclude HEALWELL AI*
2) *Definition of Care Interactions = patient visits plus technology interactions*

WELL Health Technologies Corp.
(TSX: WELL)

Core Operating Business & Capital Allocation Focus

Canadian Clinics Network

- Primary Care
- Diagnostics & Specialty Care
- Preventative & Exec Health

Strategically Controlled Operating Platforms[1]

- WELLSTAR – Future IPO
- HEALWELL – TSX: AIDX

WELL Health USA
(Divestiture Process in Progress)

1) Strategically Controlled Operating Platforms are defined as WELL owning a majority control of the business.
2) CyberWELL is another strategically controlled operating platform, but has been excluded due to its size

Q3-2025 Earnings – Additional Topics to be Covered

Key updates on the following:

1. Canadian Clinics Update
2. WELLSTAR
3. HEALWELL AI
4. Strategic Alternatives Processes for US Assets

WELL Canadian Clinics Financial Performance

WELL Canadian Clinics Annual Revenue Growth

(C$ in 000s)



WELL Canadian Clinics Annual Adj. EBITDA Growth

(C$ in 000s)



WELL Canadian Clinics Count[1]



1) 5 Clinics were added in Q3-25

WELL Providers Are Seeing more Patients

WELL Canadian Clinics Patient Visits



Billable Providers in WELL's Canadian Clinics Network



Patient Visit / Billable Provider



WELL Health TECHNOLOGIES CORP

WELL Canada Experiencing Accelerating Growth





1) WELL Canada includes Canadian Clinics, WELLSTAR and CYBERWELL

WELL Canadian Clinic Capital Allocation Track Record

Includes all acquired and absorbed clinics across cohorts, showing effective multiple performance over time.

Deal and Effective[1] Total Consideration/Sh. EBITDA Multiples



	2018-2020[2]	2021	2022[3]	2023	2024	Total	Total exc. MyHealth
Total Consideration	$22.4M	$230.3M	$5.8M	$7.4M	$14.8M	$280.7M	$64.5M
Number of Transactions	6	5	4	6	10	31	30
Acquired Revenue	$39M	$105M	$20M	$57M	$53M	$273M	$173M
Adj. EBITDA Growth[4] (%)	100%	102%	283%	nmf	91%	**117%**	**164%**

1) *Effective multiple is based on LTM Adj. EBITDA.*
2) *Excludes one-time bad debt expense.*
3) *The sum of Adj. EBITDA for the 2023 cohort of deals at close was negative.*
4) *Adj. EBITDA growth excludes one-time clinic transformation costs and shared services.*

WELL Health TECHNOLOGIES CORP

Canadian Clinic Recent M&A Activity

2025 clinic transactions to date with corresponding revenue and billable provider metrics

Q1-2025	Q2-2025	Q3-2025
+11 Clinics 4 transactions	**+3 Clinics** 3 transactions	**+5 Clinics** 5 transactions
+$31.5M Annual Revenue	**+$8.0M** Annual Revenue	**+$27.5M** Annual Revenue
+71 Providers Total Canadian Clinics	**+46 Providers** Total Canadian Clinics	**+81 Providers** Total Canadian Clinics

Increased Pace of Canadian Clinical Transactions

Includes all acquired and absorbed clinics across annual cohorts

Number of Transactions



Revenue Acquired & Absorbed



WELL Health
TECHNOLOGIES CORP

Largest M&A Pipeline of Canadian Clinics under LOI

WELL continues to execute on a robust pipeline, driving growth and sustaining strong operational momentum.

Under LOI: Canadian Clinics	~$235M Revenue	8 Signed LOIs	61 Clinics
Under LOI: Total WELL[1]	~$250M Revenue	12 Signed LOIs	
Total WELL Pipeline[2]	$350M+ Revenue	35+ Targets Engaged	130+ Clinics

1) *HEALWELL AI's LOIs are included*
2) *The Total WELL Pipeline includes potential deals that are under LOI and in the pre-LOI stage.*

WELLSTAR: Financing and Other Corporate Updates

High-quality institutional backing reinforces WELLSTAR's leadership as a high-growth, pure-play SaaS healthcare company preparing for public listing in 2026.

Key Financing Terms

$62M Series B Financing

Financing led by Mawer, Edgepoint, and PICTON

50% Premium over Series A Shares ($535M valuation)

Expected Close: Dec 2025

IPO Update

Dec 2024
Series A Financing + Microquest & Bluebird iT

Oct 2025
Signed agreement to acquire a billing co.[1] and Mutuo

Dec 2025
Series B Financing

Late 2025 – Early 2026
Additional M&A to approach 100M run-rate rev

2026
TSX IPO

1) The closing of this transaction is subject to regulatory approval

WELLSTAR: Continued Financial Out-performance

Revenue (IFRS)[1]

(C$ in 000s)



Monthly Recurring Revenue (MRR)

(C$ in 000s)



Adj. EBITDA[2]



1) *WELLSTAR's revenue in the chart includes intercompany revenues.*
2) *WELLSTAR's Adj. EBITDA excludes Shared Services expenses.*

WELL Health TECHNOLOGIES CORP

HEALWELL AI – Now a Pure-Play Global SaaS, Services & AI Company Serving Health Systems and Life Sciences Sector

Revenue (IFRS)[1]



Adj. EBITDA



Commentary

- WELL has acquired Polyclinic, two clinics in the GTA
- WELLSTAR has acquired Mutuo Health Solutions, a key part of the Nexus AI platform.
- A 50/50 clinical research JV has formed between WELL Clinics and HEALWELL while the clinical research business is under strategic review

1) *Reported figures reflect HEALWELL's consolidated continuing operations. The difference between these amounts and what WELL reports in its financials relates to discontinued operations that are consolidated at the WELL level. These can be reconciled to WELL's disclosures in WELL's Q3 MD&A.*

Strategic Alternatives Processes for US Assets

wisp

CRH Medical CORPORATION
A WELL Health Company

Circle Medical

Q3-2025 Financial Highlights: Record Revenue & Adj EBITDA

Revenue (IFRS)

(C$ in 000s)



Adj. EBITDA

(C$ in 000s)



(1) Q3-2024 figures were restated.
(2) CM Net Impact represents the impact of Circle Medical's deferred revenue adjustments on the given financial metric for the period shown.

WELL Health TECHNOLOGIES CORP

Q3-2025 Financial Highlights – Record Adj. Net Income



(1) Q3-2024 figures were restated.
(2) CM Net Impact represents the impact of Circle Medical's deferred revenue adjustments on the given financial metric for the period shown

Q3-2025 Financial Highlights – FCFA2S



WELL Health TECHNOLOGIES CORP

Outlook: 2025 and Beyond

2025 Guidance:
$1.40-1.45B Revenue
$190-210M Adj. EBITDA

2025 Guidance exc. CM[1]
$1.36-1.41B Revenue
$150-170M Adj. EBITDA

Strategic Alternatives Being Executed on for All US Care Businesses

WELL Canada
>40% Adj. EBITDA Growth[2] for 2025

WELL Canada
1.5-Yr Target[2] of
>$800M Revenue
>$100M Adj. EBITDA

1) *This guidance excludes the effect of deferred revenue from WELL's majority owned subsidiary, Circle Medical. For more information regarding this impact, please refer to WELL's Q3-25 MD&A*
2) *WELL Canada includes Canadian Clinics and WELLSTAR. Targets are Inclusive of acquisitions.*

WELL Health TECHNOLOGIES CORP

Contact

Hamed Shahbazi
CEO, Chairman & Founder
hamed@well.company

Tyler Baba
Investor Relations
investor@well.company

www.well.company
550-375 Water Street
Vancouver, BC V6B 5C6
Canada

WELL Health
TECHNOLOGIES CORP